logo
Share SHARE
FONT-SIZE Plus   Neg

Aurobindo Pharma Gets Final Approvals For Quetiapine Fumarate Tablets

Manufacturer of generic pharmaceuticals and active pharmaceutical ingredients Aurobindo Pharma Ltd. announced that the company had obtained final approvals from the US Food & Drug Administration or US FDA to market Quetiapine Fumarate tablets 25mg, 50mg, 100mg, 150mg, 200mg, 300mg and 400mg.

Quetiapine Fumarate tablets 25mg, 50mg, 100mg, 150mg, 200mg, 300mg and 400mgare the generic equivalent of AstraZeneca LP's Seroquel tablets 25mg, 50mg, 100mg, 150mg, 200mg, 300mg and 400mg. These tablets are indicated for the treatment of serious psychotic disorders such as Schizophrenia and Bipolar Disorder and fall under the Neurological (CNS) therapeutic category.

The company said the product had been approved out of Unit III facility in Hyderabad, India.

Aurobindo now has a total of 147 ANDA approvals (118 final approvals and 29 tentative approvals)from US FDA.

AT the BSE, Aurobindo Pharma shares are currently trading at Rs.116.55, up 1.66 percent from the previous close.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

More Breaking News

0 Articles
Editors Pick
Tesla Motors Inc. voluntarily recalled more than 7000 charging adapters. The company said these adapters of Nema 14-30, 10-30 and 6-50 are sold separately as accessories. Earlier in November, two customers had complained about overheating issue of Nema 14-30 charging adapters. Tesla confirmed in its recall communication that there were no other similar incidents or reports of injuries or proper Sony announced Project Field, a new play way to bring card games to life, along with a host of smartphone games at an event in Japan, aiming to accelerate mobile drive. Project Field is a Japan-only card collection platform where actual physical cards will work with a smartphone app. The first title to be announced is based on Yo-kai Watch for mobile. There is no news about an international releas Shares of Credit Suisse Group AG gained around 8 percent in the morning trading in Zurich after the Swiss banking giant raised its group cost savings target, and also confirmed its medium-term 2018 pre-tax income target.
comments powered by Disqus
Follow RTT